What is the safety and tolerability profile for LYRICA?
A1: More than 10,000 patients have taken LYRICA across all clinical programs, including over 2,000 with painful DPN and PHN. Adverse reactions were generally mild to moderate and dose related. They resolved before the final dose in the majority of patients. In all pre-marketing controlled clinical studies, the adverse reactions most frequently leading to discontinuation were dizziness (4% vs <1% for placebo) and somnolence (3% vs. <1% for placebo).
